Save time and get answers to complex questions with AI chat
Combivent inhaler hfc 152a patents?Dabrafenib mesylate when the patent is expiring in india?Albendazole side effects in humans?What excipients are combined with ruxolitinib in apotex's medication?Abbvie humira patent cliff navigation success?
See the DrugPatentWatch profile for Saphnelo
Yes. Saphnelo (anifrolumab) is used to treat certain people with moderate to severe systemic lupus erythematosus (SLE). It targets type I interferon signaling, which is part of the inflammatory pathway in lupus. [1]
Saphnelo is indicated for systemic lupus erythematosus (SLE), not discoid lupus. It is intended for patients with active disease where treatment with other therapies may not fully control symptoms. [1]
Saphnelo is given as an intravenous infusion in a clinical setting. [1]
Common safety concerns for lupus biologics include risks related to immune effects, such as infections; patients generally need monitoring and should report fever or signs of infection promptly. [1]
[1] https://www.drugpatentwatch.com/
Other Questions About Saphnelo :